Cutaneous Angiosarcoma of Head and Neck – A Single-Centre Analysis
Abstract
BACKGROUND: Cutaneous angiosarcoma of the head and neck region is a subtype of cutaneous angiosarcoma with an unfavourable prognosis. Diagnosis is often delayed.
PATENTS AND METHODS: The setting is an Academic Teaching Hospital Skin Cancer Center. Eight Caucasian patients could be identified, 5 men and 3 women. Delay to diagnosis was between 12 to 4 months (mean 7.8 ± 2.9 months). The diagnosis was confirmed in all cases by histopathology and immunohistochemistry. Hematoxylin-eosin, Giemsa, PAS, iron and reticulin stains were performed. Endothelial markers such as CD31, CD34, and Ki67 for proliferation assessment were used in all tumours. Other markers used included pan-cytokeratin (CK), CK7, CK20, ERG, CD 40 and c-MYC. Tumours were classified as localised versus multifocal or diffuse form. Tumour staging was performed according to the 8th edition of the AJCC. The mean age of patients was 79 years ± 26.4 years. The male to female ratio was 1.7. Tumour classification was diffuse in 2 patients, multilocular in one and localised in 5 patients. In 5 of 8 patients, a multimodal treatment was performed, one had radiotherapy alone, in another patient surgery was performed, and radiotherapy is planned. The mean OS was 26.4 months ± 24.5 months.
CONCLUSION: Cutaneous angiosarcoma of the head and neck is an aggressive tumour with a poor prognosis. Although surgery remains a cornerstone of treatment, the tumour size at first presentation may be too large, and the elderly patients maybe not suitable for extensive surgery. Therefore, multimodal treatment with adjuvant radiotherapy and/ or chemotherapy is necessary. Multimodal treatment offers a better outcome than radiotherapy or chemotherapy alone. Stealth liposomal encapsulated doxorubicin is a therapeutic option for elderly patients with improved safety compared to conventional doxorubicin.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010; 11(10):983-91. https://doi.org/10.1016/S1470-2045(10)70023-1
Albores-Saavedra J, Schwartz AM, Henson DE, Kostun L, Hart A, Angeles-Albores D, Chablé-Montero F. Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007. Ann Diagn Pathol. 2011; 15(2):93-7. https://doi.org/10.1016/j.anndiagpath.2010.07.012 PMid:21190880
Bernstein JM, Irish JC, Brown DH, Goldstein D, Chung P, Razak ARA, Catton C, Gilbert RW, Gullane PJ, O'Sullivan B. Survival outcomes for cutaneous angiosarcoma of the scalp versus face. Head Neck. 2017; 39(6):1205-1211. https://doi.org/10.1002/hed.24747 PMid:28398688
Amin MB, Greene FL, Edge S, Schilsky RL, Gaspar LE, Washington MK, Sullivan DC, Brookland RK. AJCC Cancer Staging Manual, 8th Edition. Springer International, New York, 2017.
Oashi K, Namikawa K, Tsutsumida A, Takahashi A, Itami J, Igaki H, Inaba K, Yamazaki N. Surgery with curative intent is associated with prolonged survival in patients with cutaneous angiosarcoma of the scalp and face -a retrospective study of 38 untreated cases in the Japanese population. Eur J Surg Oncol. 2018; 44(6):823-829. https://doi.org/10.1016/j.ejso.2018.02.246 PMid:29555155
Wollina U, Hansel G, Schönlebe J, Averbeck M, Paasch U, Uhl J, Hindemann W, Simon J-C. Cutaneous angiosarcoma is a rare aggressive malignant vascular tumour of the skin. J Eur Acad Dermatol Venereol. 2011; 25(8):964-8. https://doi.org/10.1111/j.1468-3083.2010.03905.x PMid:21108661
Patel SH, Hayden RE, Hinni ML, Wong WW, Foote RL, Milani S, Wu Q, Ko SJ, Halyard MY. Angiosarcoma of the scalp and face: the Mayo Clinic experience. JAMA Otolaryngol Head Neck Surg. 2015; 141(4):335-40. https://doi.org/10.1001/jamaoto.2014.3584 PMid:25634014
Hwang K, Kim MY, Lee SH. Recommendations for therapeutic decisions of angiosarcoma of the scalp and face. J Craniofac Surg. 2015; 26(3):e253-6. https://doi.org/10.1097/SCS.0000000000001495 PMid:25901670
Ogawa K, Takahashi K, Asato Y, Yamamoto Y, Taira K, Matori S, Iraha S, Yagi N, Yogi A, Haranaga S, Fujita J, Uezato H, Murayama S. Treatment and prognosis of angiosarcoma of the scalp and face: a retrospective analysis of 48 patients. Br J Radiol. 2012; 85(1019):e1127-33. https://doi.org/10.1259/bjr/31655219 PMid:22806620 PMCid:PMC3500812
Letsa I, Benson C, Al-Muderis O, Judson I. Angiosarcoma of the face and scalp: effective systemic treatment in the older patient. J Geriatr Oncol. 2014; 5(3):276-80. https://doi.org/10.1016/j.jgo.2014.02.004 PMid:24685486
Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, van Oosterom AT, Clemons MJ, Kamby C, Hermans C, Whittaker J, Donato di Paola E, Verweij J, Nielsen S. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001; 37(7):870-7. https://doi.org/10.1016/S0959-8049(01)00050-8
Toma S, Tucci A, Villani G, Carteni G, Spadini N, Palumbo R. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Anticancer Res. 2000; 20(1B):485-91.
Wollina U. Liposomal cancer chemotherapy in dermatology: current status and future prospects. Indian J Dermatol. 2004; 49(3):109-116.
Copyright (c) 2019 Uwe Wollina, André Koch, Gesina Hansel, Jacqueline Schönlebe, Torello Lotti, Aleksandra Vojvodic (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All rights reserved.
